Akebia Therapeutics (AKBA) Misses Q2 EPS by 3c

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $59.1 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• MotorK names Roy Toren to board as Helen Protopapas resigns
• Vafseo trial stopped early after interim data shows fewer hospitalizations